Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: Retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas

Modern Pathology

Volumn 26, Issue 10, 2013, Pages 1401-1412

  Djordjevic, Bojana ^a,b   Barkoh, Bedia A ^a   Luthra, Rajyalakshmi ^a   Broaddus, Russell R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

DNA mismatch repair; Endometrial cancer; PTEN

Indexed keywords

MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGED; CANCER PATIENT; CANCER SCREENING; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DIAGNOSIS, DIFFERENTIAL; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PTEN PHOSPHOHYDROLASE;

EID: 84885022788     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.67     Document Type: Conference Paper

References (59)

1. Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer o/=70 years. Gynecol Oncol 2012;125: 414-420.
2. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66: 7810-7817.
3. Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6: 3607-3613.
4. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106: 87-94.
5. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57: 4736-4738.
6. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17: 143-144.
7. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res 2010;16: 4325-4330.
8. Djordjevic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012;25: 699-708.
9. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92: 924-930.
10. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61: 4311-4314.
11. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58: 3254-3258.
12. Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996;56: 1917-1921.
13. Cohn DE, Basil JB, Venegoni AR, et al. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000; 79: 101-106.
14. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57: 3935-3940.
15. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31: 312-317.
16. Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006;119: 563-570.
17. Kanaya T, Kyo S, Sakaguchi J, et al. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 2005; 124: 89-96.
18. Peiro G, Lohse P, Mayr D, et al. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl- 2 expression, microsatellite instability status, and outcome. Am J Clin Pathol 2003;120: 78-85.
19. Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4: 3005-3010.
20. An HJ, Kim KI, Kim JY, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007;31: 846-853.
21. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res 2011;17: 1331-1340.
22. Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115: 32-38.
23. An HJ, Logani S, Isacson C, et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004;17: 530-537.
24. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88: 814-824.
25. Duggan BD, Felix JC, Muderspach LI, et al. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86: 1216-1221.
26. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148: 1671-1678.
27. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81: 214-218.
28. Garg K, Broaddus RR, Soslow RA, et al. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012;31: 48-56.
29. Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol 2010;27: 261-273.
30. Garg K, Leitao MM Jr., Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009;33: 925-933.
31. Zhou XP, Kuismanen S, Nystrom-Lahti M, et al. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 2002;11: 445-450.
32. Djordjevic B, Hennessy BT, Li J, et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry out-performs gene sequencing. Mod Pathol 2012;25: 699-708.
33. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011;1: 170-185.
34. Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009;22: 522-529.
35. Garg K, Shih K, Barakat R, et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 2009;33: 1869-1877.
36. Alkushi A, Clarke BA, Akbari M, et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007; 20: 1156-1165.
37. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012;228: 20-30.
38. Catasus L, D'Angelo E, Pons C, et al. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations. Mod Pathol 2010;23: 694-702.
39. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012;9: 48-57.
40. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010;22: 473-480.
41. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96: 261-268.
42. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107: 159-162.
43. Westin SN, Lacour RA, Urbauer DL, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008;26: 5965-5971.
44. Garg K, Soslow RA. Lynch syndrome (hereditary nonpolyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009;62: 679-684.
45. Berends MJ, Wu Y, Sijmons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002;70: 26-37.
46. Mercado RC, Hampel H, Kastrinos F, et al. Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 2012;14: 670-680.
47. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155: 69-79.
48. Resnick K, Straughn JM Jr., Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 2009;114: 530-536.
49. Bartley AN, Luthra R, Saraiya DS, et al. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res (Phila) 2012; 5: 320-327.
50. Baudhuin LM, Burgart LJ, Leontovich O, et al. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005;4: 255-265.
51. Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29: 2247-2252.
52. Bellcross CA, Bedrosian SR, Daniels E, et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Genet Med 2012;14: 152-162.
53. Kalloger SE, Allo G, Mulligan AM, et al. Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices. Am J Surg Pathol 2012;36: 560-569.
54. Deng G, Nguyen A, Tanaka H, et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer 2006;118: 2999-3005.
55. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41: 664-668.
56. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007;6: 301-310.
57. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3: 101-107.
58. Peterson LM, Kipp BR, Halling KC, et al. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. Int J Gynecol Pathol 2012;31: 195-205.
59. Mutch DG, Powell MA, Mallon MA, et al. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004; 190: 935-942.